Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CARCIK-CD22
- Development stage
- Preclinical
- Lead developer
- Fondazione Matilde Tettamanti
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CARCIK-CD22 is an investigational donor-derived, non-viral chimeric antigen receptor (CAR) cytokine-induced killer (CIK) cell therapy engineered to target CD22. Developed using a Sleeping Beauty (SB) transposon-based platform, CARCIK-CD22 is designed to treat B-cell acute lymphoblastic leukemia (B-ALL), particularly in patients who have relapsed or are resistant to anti-CD19 CAR-T cell therapies. The therapy utilizes healthy donor peripheral blood mononuclear cells (PBMCs) electroporated with SB plasmids encoding the anti-CD22 CAR, offering a multi-targeting strategy to prevent and address post-CAR-T leukemia relapses.
- Other names
- CAR-CIK CD22CARCIK CD22
Beyond the preview
Go deeper on CARCIK-CD22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CARCIK-CD22.